We see that HARP’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. Revisions could be a useful indicator to get insight on short-term price movement so for the company, there were no upward and no downward review(s) in last seven days.
Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $26.79 million, representing an increase of 13.30% from the revenues reported in the last year’s results.
Data indicates that the EPS growth is expected to be 37.30% in 2023, while the next year’s EPS growth is forecast to be -4.80%.Īccording to the average forecast, sales growth in current quarter could jump up 19.20%, compared to the corresponding quarter of last year. Analysts are projecting the company’s earnings per share (EPS) to be -$0.56, which is expected to increase to -$0.15 for fiscal year -$2.27 and then to about -$2.38 by fiscal year 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. (NASDAQ:HARP) was part of 12 public stock portfolios at the end of Q1 2022, compared to 14 funds in the earlier quarter. currently standing at about $77.34 million, investors are eagerly awaiting this quarter’s results, scheduled for – Mar 14, 2022. Among the hedge funds tracked by Insider Monkey, Harpoon Therapeutics, Inc. With the market capitalization of Harpoon Therapeutics Inc.
Harpoon therapeutics stock free#
Sign up here to get your free report now. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest. While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well.
0 kommentar(er)
